No Data
No Data
Possible Bearish Signals With 10x Genomics Insiders Disposing Stock
Over the past year, many 10x Genomics, Inc. (NASDAQ:TXG) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually mo
10x Genomics Is Maintained at Overweight by Barclays
10x Genomics Is Maintained at Overweight by Barclays
Express News | 10X Genomics : Barclays Cuts Target Price to $24 From $36
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $24
Barclays analyst Luke Sergott maintains $10x Genomics(TXG.US)$ with a buy rating, and adjusts the target price from $36 to $24.According to TipRanks data, the analyst has a success rate of 39.9% and a
Cathie Wood's Top and Bottom Performing ARKK Holdings of H1
New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies
Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire